Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

DRL performance in 6-hydroxydopamine-treated rats

T E Levine, P S McGuire, T G Heffner

    Pharmacology, Biochemistry, and Behavior
    |February 1, 1980
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Neurotoxicity of methamphetamine and methylenedioxymethamphetamine.

    Neurotoxicity research·2004
    Same author

    Thiazoloindans and thiazolobenzopyrans: a novel class of orally active central dopamine (partial) agonists.

    Journal of medicinal chemistry·2000
    Same author

    Synthesis and pharmacological evaluation of thiopyran analogues of the dopamine D3 receptor-selective agonist (4aR,10bR)-(+)-trans-3,4,4a,10b-tetrahydro-4-n-propyl-2H,5H [1]b enzopyrano[4,3-b]-1,4-oxazin-9-ol (PD 128907).

    Journal of medicinal chemistry·2000
    Same author

    The serotonin-1A receptor antagonist WAY-100635 modifies fluoxetine's antidepressant-like profile on the differential reinforcement of low rates 72-s schedule in rats.

    Psychopharmacology·2000
    Same author

    PD 158771, a potential antipsychotic agent with D(2)/D(3) partial agonist and 5-HT(1A) agonist actions. I. Neurochemical effects.

    Neuropharmacology·2000
    Same author

    PD 158771, a potential antipsychotic agent with D2/D3 partial agonist and 5-HT(1A) agonist actions. II. Preclinical behavioral effects.

    Neuropharmacology·2000

    6-hydroxydopamine (6-HDA) did not affect rats' ability to learn or maintain performance on a differential reinforcement of low rate (DRL) schedule. However, 6-HDA blocked amphetamine's rate-increasing effects.

    Area of Science:

    • Neuroscience
    • Behavioral Neuroscience
    • Psychopharmacology

    Background:

    • Dopamine and norepinephrine are critical neurotransmitters involved in reward and motivation.
    • The differential reinforcement of low rate (DRL) schedule is a behavioral paradigm used to study response inhibition and timing.
    • 6-hydroxydopamine (6-HDA) is a neurotoxin that selectively destroys dopaminergic and noradrenergic neurons.

    Purpose of the Study:

    • To investigate the role of central dopaminergic and noradrenergic systems in the acquisition and maintenance of DRL performance.
    • To examine the effects of dopamine and norepinephrine depletion on the behavioral effects of amphetamine in a DRL task.

    Main Methods:

    • Adult rats received intraventricular injections of 6-hydroxydopamine (6-HDA) or a vehicle control.

    Related Experiment Videos

  • Following neurochemical treatment, rats were trained and tested on a differential reinforcement of low rate (DRL) 18-sec schedule of water reinforcement.
  • The effects of amphetamine administration on DRL performance were assessed in both control and 6-HDA-treated rats.

    • Main Results:

    • 6-HDA treatment resulted in significant depletions of dopamine and norepinephrine in the brain.
    • Despite neurochemical depletions, 6-HDA did not alter the acquisition or maintenance of DRL performance.
    • 6-HDA completely blocked the response rate-increasing effects of amphetamine but did not affect its rate-decreasing effects on DRL performance.

    Conclusions:

    • Central dopaminergic and noradrenergic systems are not essential for the acquisition or maintenance of DRL 18-sec schedule performance.
    • The integrity of these catecholamine systems is necessary for the rate-increasing, but not the rate-decreasing, effects of amphetamine in this DRL task.
    • Rats with depleted catecholamine levels can still respond to the contingencies required for reinforcement on a DRL schedule.